The Glass Half-Empty: Why Science is Toasting Goodbye to “Heart-Healthy” Drinking

For decades, the public has been told that a daily glass of wine might be the secret to longevity. This belief largely stems from the so-called J-shaped curve—a statistical pattern suggesting that light drinkers experience better cardiovascular outcomes than both heavy drinkers and people who abstain entirely. The implication was comforting: a little alcohol could be protective. Yet as modern epidemiology has evolved, researchers have begun to question whether this “cardioprotective” effect reflects biology—or bias. Increasingly, the evidence suggests that what appeared to be a benefit may in fact be a statistical illusion.

Much of the perceived advantage of moderate drinking weakens under closer scrutiny. One major issue is the “Sick Quitter” bias: individuals who stop drinking due to illness are often grouped with lifelong abstainers, making the non-drinking population appear less healthy than it truly is. Another distortion, the “Healthy User” bias, reflects the fact that moderate drinkers often have higher socioeconomic status, healthier diets, better access to healthcare, and more active lifestyles. In such cases, alcohol may look like the protective factor when it is merely accompanying healthier behaviors. To address these distortions, scientists increasingly rely on Mendelian randomization—essentially a natural experiment in which genetic variants related to alcohol metabolism, such as ADH1B, are randomly assigned at conception. Because genes are not shaped by lifestyle or income, they provide a more unbiased lens. Large-scale Mendelian randomization studies have largely failed to confirm a protective cardiovascular effect. Instead, they frequently demonstrate a linear increase in risks for hypertension and coronary artery disease across rising levels of alcohol consumption.

While debates about clogged arteries persist, the evidence surrounding atrial fibrillation (AF)—a potentially dangerous irregular heart rhythm—is far more definitive. Here, there is no J-shaped curve and no protective “sweet spot.” The relationship appears strictly linear: for every additional daily drink, the risk of AF rises by approximately 6% to 8%. Even isolated binge episodes can trigger acute arrhythmias, a phenomenon known as “Holiday Heart Syndrome.” These episodes demonstrate how sensitive the heart’s electrical system is to alcohol exposure. When it comes to cardiac rhythm, there appears to be no safe threshold below which risk disappears.

The long-celebrated “French Paradox” further illustrates how appealing narratives can outpace scientific rigor. The theory suggested that red wine, rich in polyphenols such as resveratrol, explained low rates of heart disease in certain wine-drinking populations. However, when researchers carefully adjust for lifestyle differences—such as smoking rates, exercise habits, and dietary quality—the supposed “wine advantage” largely fades. Wine drinkers tend to engage in other health-promoting behaviors, making it difficult to isolate any unique pharmacologic benefit from the beverage itself. Ultimately, the body metabolizes ethanol the same way regardless of whether it comes from wine, beer, or spirits. The romantic image of red wine as a cardiovascular superfood appears far more cultural than clinical.

Alcohol’s relationship with stroke provides one of the clearest examples of its double-edged nature. On one hand, alcohol’s mild anti-thrombotic properties may slightly reduce the risk of ischemic stroke, which occurs when a clot blocks blood flow to the brain. On the other hand, this same blood-thinning effect impairs the body’s ability to stop bleeding. Combined with the blood pressure spikes that accompany drinking—particularly binge drinking—the risk of hemorrhagic stroke, or bleeding within the brain, increases steadily with higher consumption. Thus, any modest reduction in clot-related stroke risk may be offset—or even outweighed—by a rising risk of catastrophic brain hemorrhage.

Not all findings are bleak. Chronic heavy alcohol use—commonly defined as consuming approximately 80 grams of ethanol daily for at least five years—can lead to alcoholic cardiomyopathy (ACM), a condition in which the heart muscle weakens and dilates. Unlike many other forms of heart failure, however, ACM carries a rare and important silver lining: it is often reversible. With sustained abstinence, patients frequently experience significant recovery in heart function, sometimes regaining near-normal cardiac performance. This reversibility underscores both the damage alcohol can inflict and the remarkable resilience of the human heart when the toxic exposure is removed.

In light of these evolving findings, global health authorities such as the World Health Organization and the American Heart Association have shifted their messaging. Rather than endorsing moderate drinking for heart health, current guidance emphasizes that less is better—and that abstinence carries no cardiovascular penalty. The accumulating genetic and epidemiological evidence suggests that the safest level of alcohol consumption may in fact be zero. If the reassuring image of a “heart-healthy” toast was built on methodological bias rather than biological protection, the real question becomes not whether alcohol is beneficial, but whether we still need to believe it is.

---

READ MORE: DEEP DIVE HERE:

The Cardiovascular Effects of Alcohol Consumption: Dose-Response Relationships and Beverage Type Differences

Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality globally, necessitating a rigorous evaluation of modifiable risk factors, among which alcohol consumption occupies a uniquely controversial position.[1] For decades, the medical community has observed a persistent J-shaped or U-shaped association in epidemiological data, wherein light-to-moderate consumers appear to have a lower risk of coronary heart disease (CHD) and ischemic stroke compared to both abstainers and heavy drinkers.[1] This observation, frequently termed the “cardioprotective effect,” has been attributed to a variety of physiological mechanisms, including favorable shifts in lipid profiles, improved insulin sensitivity, and anti-clotting effects.[2] However, recent advancements in genetic epidemiology—most notably Mendelian randomization—and more robust adjustments for confounding variables have begun to challenge the validity of this perceived benefit.[3,4] This report provides an exhaustive analysis of the dose-response relationship between alcohol and cardiovascular health, differentiating between beverage types, exploring underlying biological mechanisms, and evaluating the net clinical impact on mortality and population-specific risks.[1]

Metabolic Pathways and the Biochemistry of Ethanol

The cardiovascular impact of alcohol begins with its metabolic transformation in the liver and subsequent interaction with systemic tissues.[2] Ethanol is primarily oxidized via a two-step enzymatic process.[2] First, alcohol dehydrogenase (ADH) converts ethanol into acetaldehyde, a highly reactive and toxic metabolite.[2] Second, aldehyde dehydrogenase (ALDH) converts acetaldehyde into acetate, a relatively benign substance that is eventually broken down into carbon dioxide and water.[2]

The efficiency of this pathway is a critical determinant of individual susceptibility to alcohol-related harm.[5] In populations with high frequencies of the ALDH2*2 allele, particularly in East Asia, the second step of metabolism is impaired, leading to the accumulation of acetaldehyde.[5] This accumulation results in the “flushing syndrome” characterized by facial erythema, tachycardia, and nausea, and serves as a natural deterrent to heavy consumption.[5] However, for those who continue to drink despite this genetic predisposition, the elevated levels of acetaldehyde exert direct cardiotoxic effects, promoting oxidative stress and damaging cellular junctions.[5-7]

The metabolic process also significantly alters the cellular redox state.[2] The conversion of ethanol and acetaldehyde requires the reduction of nicotinamide adenine dinucleotide (NAD+) to NADH.[2] The resulting increase in the NADH/NAD+ ratio suppresses gluconeogenesis and shifts hepatic metabolism toward fatty acid synthesis, contributing to hypertriglyceridemia and potentially accelerating the early stages of atherosclerosis in heavy drinkers.[2]

Dose-Response Relationships: The J-Shaped Curve Re-evaluated

Central to the discussion of alcohol and cardiovascular health is the definition of consumption levels and the standard drink.[8] In the United States, a standard drink contains approximately 14 grams of pure ethanol, though international definitions vary.[8]

Consumption Category	Definitions (Standard Drinks/Day)	Typical Ethanol Equivalent (g/day)
Low Consumption	< 1 drink/day	< 14g
Moderate Consumption	1–2 drinks/day (Men), 1 drink/day (Women)	14g – 28g
High/Heavy Consumption	> 3–4 drinks/day or Binge episodes	> 42g
Binge Drinking	>= 5 (Men) or >= 4 (Women) in ~2 hours	>= 70g

Observational Evidence for Cardioprotection

Traditional prospective cohort studies have consistently identified a J-shaped curve for various cardiovascular outcomes.[1] A recent meta-analysis of observational data indicated that moderate drinkers experience a 12% lower risk of myocardial infarction (RR = 0.88) and an 11% lower risk of total stroke (RR = 0.89) compared to never-consumers.[1,9] This numeric alignment is important: an RR of 0.88 corresponds to a 12% relative reduction, not a 22% reduction, and careful reporting of effect sizes prevents overstatement while preserving interpretability across outcomes.[1,9] The nadir of this curve, representing the lowest risk, is typically observed at consumption levels of approximately 1 to 2 drinks per day for coronary heart disease and <= 1 drink per day for stroke mortality.[1]

Methodological Bias and Causal Inference

The perceived protective effect of moderate drinking is increasingly scrutinized due to several endemic biases in observational research:[1]

1. Sick Quitter Bias: Former drinkers, who may have abstained due to alcohol-related health issues or medications, are often grouped with life-long abstainers. This makes the “moderate” drinking group appear healthier by comparison.[1]
2. Healthy User Bias: Moderate alcohol consumption is often a marker for higher socioeconomic status, better dietary habits (such as the Mediterranean diet), and increased physical activity—all of which independently reduce cardiovascular risk.[1]
3. Underreporting: Self-reported data often underestimate actual intake, potentially leading to the misclassification of heavy drinkers as moderate ones.[2]

Mendelian randomization (MR) studies, which use genetic variants like ADH1B (rs1229984) and ALDH2 (rs671) as instrumental variables, have provided a different perspective.[3,4] Because alleles are randomly assigned at conception, they are less prone to the lifestyle confounders that plague observational studies.[3,4] Large-scale MR analyses, including data from the Million Veteran Program and UK Biobank, have largely failed to support the protective effect.[3,4] Instead, they often demonstrate a linear increase in risks for hypertension and coronary artery disease across all levels of alcohol consumption, suggesting that any benefit observed in traditional studies is likely non-causal.[3,4]

Alcohol and the Pathogenesis of Atherosclerosis

Atherosclerosis, the thickening and hardening of arterial walls due to plaque accumulation, is the underlying cause of most cardiovascular events.[2] Alcohol’s effect on this process is multi-factorial, involving lipids, inflammatory markers, and endothelial function.[2]

Lipids and Lipoproteins

One of the most robust observational findings is the positive association between alcohol intake and high-density lipoprotein (HDL) cholesterol.[2] Ethanol increases the production of apolipoproteins A-I and A-II and the transport rate of HDL subfractions.[2]

Lipid Parameter	Effect of Moderate Alcohol	Effect of Heavy Alcohol
HDL Cholesterol	Increase (HDL2 and HDL3)	Significant Increase
LDL Cholesterol	Slight decrease or No change	Variable; possible increase
Triglycerides	Minimal effect	Significant increase
Apolipoprotein A-I	Increase	Significant increase

While HDL has historically been considered “good” cholesterol, the alcohol-induced increase in HDL does not necessarily translate into a reduction in cardiovascular risk.[3,4] Mendelian randomization studies have shown that increasing HDL through alcohol does not have a clear causal link to reduced myocardial infarction risk, suggesting that the functional quality of the HDL particles or the pathways involved may be more important than the absolute concentration.[3,4]

Inflammation and Biomarkers

Low-grade systemic inflammation is a critical driver of atherosclerotic progression.[2] Moderate alcohol consumption has been associated with lower levels of C-reactive protein (CRP), fibrinogen, and Interleukin-6 (IL-6) in observational studies.[2] However, the causal nature of these associations is questionable.[20,21] One-sample and two-sample MR analyses have suggested that while CRP is a strong predictive marker for ischemic stroke and death, it does not have a causal role in these outcomes.[20] Similarly, genetic evidence suggests that the relationship between alcohol and inflammation markers may be confounded by factors like smoking and body mass index, and by correlated health behaviors that cluster with beverage choice and drinking pattern.[21]

Endothelial Function and Imaging

Healthy endothelial function is essential for vascular homeostasis, mediated primarily through nitric oxide (NO) production.[2] Moderate intake, particularly of red wine, has been shown to acutely improve flow-mediated vasodilation (FMD).[22] In contrast, chronic heavy drinking impairs endothelial function, promotes oxidative stress, and contributes to arterial stiffening.[2]

Imaging studies provide an objective look at subclinical atherosclerosis.[10,11] The relationship between alcohol and carotid intima-media thickness (cIMT) or coronary artery calcium (CAC) scores remains inconsistent.[10,11] While some Japanese studies have found lower cIMT in moderate drinkers compared to never-drinkers, larger consortia like the USE-IMT have reported more complex, often null, associations after adjusting for cardiovascular risk factors.[10] A longitudinal study in Sweden found no association between midlife alcohol intake and the presence of carotid plaque or IMT at age 60, further suggesting that the atherosclerotic benefits of alcohol may be overstated and may reflect selection and residual confounding rather than durable plaque-level protection.[11]

Cardiac Arrhythmogenesis: Atrial Fibrillation and Beyond

While alcohol may have mixed effects on coronary disease, its role as a pro-arrhythmic agent is well-established.[12,28] The most common arrhythmia associated with alcohol use is atrial fibrillation (AF).[12,28]

Atrial Fibrillation and the “Holiday Heart”

The association between heavy alcohol consumption and new-onset AF, often occurring after binge episodes, is known as “Holiday Heart Syndrome”.[28] However, even moderate consumption is linked to a heightened risk.[12,15] Meta-analyses of over 10 million participants show that for every additional drink per day (often modeled as ~12 g ethanol/day increments), the risk of AF increases by approximately 6% to 8%.[9,12]

Parameter	Impact of Alcohol on AF Risk
Dose-Response	Linear in men; potentially J-shaped in women
Risk per Drink	6% – 8% increase per ~12g ethanol/day
Binge Drinking	Significant acute trigger for episodes
Recurrence	Alcohol abstainers have lower recurrence after ablation

Electrophysiological and Structural Mechanisms

The mechanisms by which alcohol induces AF are both acute and chronic:[28,29,31]

1. Electrophysiological Changes: Alcohol acutely shortens the effective refractory period (ERP) of the atria, particularly in the pulmonary veins, making the heart more susceptible to re-entrant circuits.[28]
2. Structural Remodeling: Chronic consumption is associated with left atrial enlargement and the development of low-voltage zones (fibrosis), which serve as substrates for persistent AF.[28]
3. Autonomic Nervous System: Alcohol stimulates the sympathetic component while reducing heart rate variability, creating a state of autonomic imbalance that favors arrhythmias.[28]
4. Ion Channel Modulation: Ethanol and acetaldehyde can disrupt L-type calcium channels and sodium channels, leading to intracellular calcium imbalance and electrical instability.[29]

Cerebrovascular Risk: The Stroke Subtype Dichotomy

The impact of alcohol on stroke is highly heterogeneous and depends heavily on the subtype (ischemic vs. hemorrhagic) and the pattern of drinking.[1,23]

Ischemic Stroke

Observational meta-analyses often report a J-shaped relationship for ischemic stroke.[1,23] Moderate drinkers (1–2 drinks/day) show a reduced risk (RR = 0.83 to 0.87), whereas heavy drinkers experience a significant increase in risk (RR = 1.31).[1,23] The perceived benefit at lower doses is thought to be mediated by alcohol’s anti-thrombotic properties, including reduced fibrinogen levels and decreased platelet reactivity.[2,24] However, MR studies using the ADH1B variant suggest that any reduction in alcohol intake is associated with a reduced risk of ischemic stroke, implying that the “cardioprotective” observational findings may be due to selection bias.[3,4]

Hemorrhagic Stroke

In stark contrast, the relationship between alcohol and hemorrhagic stroke appears to be more linear.[1,23] Current alcohol consumers have approximately a 14% increased risk for hemorrhagic stroke compared to nondrinkers, a risk that increases steadily with the amount consumed.[1,23] This is likely driven by alcohol’s effect on blood pressure and its impairment of primary hemostasis.[2] Binge drinking, in particular, causes transient but sharp increases in blood pressure that can trigger acute intracerebral hemorrhage.[2]

Myocardial Structure and Alcoholic Cardiomyopathy

Chronic heavy alcohol consumption can lead to alcoholic cardiomyopathy (ACM), a form of non-ischemic dilated cardiomyopathy characterized by ventricular dilation and impaired systolic function.[14,15]

Thresholds and Pathophysiology

ACM typically develops after long-term exposure to high levels of ethanol.[14,15] While definitions vary, the classic threshold is often cited as the consumption of more than 80 grams of ethanol per day for at least five years.[14,15] This condition accounts for a clinically meaningful fraction of non-ischemic dilated cardiomyopathies, although the exact proportion varies widely by cohort, ascertainment method, and exposure definition, and reported estimates can span broad ranges across clinical series and population studies.[15]

The pathogenesis of ACM involves:

• Direct Toxicity: Ethanol and acetaldehyde induce oxidative stress, impairing protein synthesis and causing mitochondrial dysfunction in cardiomyocytes.[15]
• Activation of the Renin-Angiotensin System: Chronic use stimulates neurohormonal pathways that promote myocardial fibrosis and remodeling.[15]
• Nutritional Deficiencies: While alcohol is a primary toxin, secondary factors like thiamine deficiency (Beriberi) can exacerbate cardiac dysfunction in some patients.[14,15]

Reversibility and Prognosis

A defining characteristic of ACM is its potential for reversibility.[14,15] Unlike idiopathic dilated cardiomyopathy, ACM often shows significant improvement in left ventricular ejection fraction (LVEF) and clinical symptoms upon total abstinence from alcohol.[15,25] Even in patients with advanced disease, early intervention and cessation of drinking can lead to a favorable prognosis and stabilization of heart failure.[15,25]

Beverage Type Comparison: Wine, Beer, and Spirits

A persistent question in cardiovascular research is whether the type of beverage consumed matters.[16,18] The “French Paradox” popularized the idea that red wine, in particular, offers unique protection due to its high concentration of polyphenols like resveratrol.[22]

Wine vs. Beer vs. Spirits

Meta-analyses of beverage types suggest that wine drinkers often have the lowest relative risk for cardiovascular mortality, followed by beer, with spirits often showing a null or less favorable effect, although the magnitude of these differences is highly sensitive to confounding control, socioeconomic patterning, and smoking-related covariation.[18]

Beverage Type	Observational Relative Risk (CVD Mortality)	Proposed Beneficial Mechanism
Wine (Red)	0.73	Polyphenols, Resveratrol, Antioxidant effects
Beer	0.80	Ethanol, Vitamin B, Hops-derived compounds
Spirits	0.98 (Neutral to High)	Primarily Ethanol-mediated effects

These estimates should be interpreted as observationally associated risks rather than causal pharmacologic effects; across datasets, effect sizes may shift toward null after fuller adjustment for diet quality, income, healthcare access, and smoking intensity, and the “wine advantage” can shrink materially when beverage choice is treated as a behavioral cluster rather than an isolated exposure.[18]

The Polyphenol Controversy

Experimental studies have demonstrated that red wine polyphenols can enhance NO bioavailability, reduce oxidative stress, and inhibit platelet aggregation more effectively than ethanol alone.[22] Some studies using dealcoholized red wine have shown that these vascular benefits can be achieved without the harmful effects of ethanol.[22]

However, the epidemiological “wine advantage” is likely heavily confounded.[18] Wine drinkers consistently buy healthier foods, have higher socioeconomic status, and are less likely to smoke compared to beer or spirit drinkers.[18] When studies are meticulously adjusted for these factors, the difference between wine and other beverage types often diminishes, suggesting that the ethanol component and the associated lifestyle may be the primary drivers of any observed benefit.[18]

Mortality Outcomes and Global Burden

The cardiovascular effects of alcohol must be situated within the broader context of global health and all-cause mortality.[17,27]

Cardiovascular vs. All-Cause Mortality

While moderate consumption may be associated with reduced cardiovascular mortality in some observational cohorts (RR = 0.82), this benefit is often offset by increases in other causes of death, particularly cancer and accidents.[1] The 2021 Global Burden of Disease (GBD) study highlights that alcohol use remains a top risk factor for global disease burden, ranking as the 10th leading risk factor for all deaths and the number one risk factor for those aged 15–49.[27]

Age Group	Cardiovascular Effect	Overall Health Impact
Ages 15–39	No health benefits; primarily risks	Significant risk of injury and acute events
Ages 40–64	Mixed; potential protective association	High cancer risk; offset mortality benefit
Ages 65+	Observational protective effects for CVD	Potential benefit; debated by genetics

Recent Trends and Regional Differences

Global deaths attributable to high alcohol use doubled between 1990 and 2021, though age-standardized mortality rates have declined in some regions due to improvements in overall healthcare.[27] Eastern Europe continues to experience the highest burden of alcohol-related CVD, while regions like Southeast Asia are seeing dramatic increases in years of life lost (DALYs) due to rising consumption levels.[27]

Genetic Variability and Population Differences

Individual responses to alcohol are not uniform and are profoundly shaped by genetics and baseline health status.[5-7]

Genetic Markers of Sensitivity

The ADH1B (rs1229984) and ALDH2 (rs671) variants are the most studied genetic determinants of alcohol-related cardiovascular risk.[3-7]

• ADH1B (rs1229984): Individuals with this variant metabolize ethanol to acetaldehyde more quickly, leading to higher levels of this toxin and generally lower alcohol consumption. These individuals consistently show a lower risk of CHD and stroke in MR studies, regardless of their self-reported intake.[3,4]
• ALDH2 (rs671): This variant, prevalent in East Asians, impairs the clearance of acetaldehyde. Carriers who continue to drink heavily have a markedly increased risk of ischemic stroke and coronary artery disease compared to non-carriers.[5-7]

Sex-Specific Differences

Women often experience higher blood alcohol concentrations for a given dose compared to men, due to lower levels of gastric alcohol dehydrogenase and a smaller volume of distribution for ethanol.[2] While observational data suggest a J-shaped curve for AF in women, the linear risk in men appears more robustly established.[12,15] Furthermore, heavy consumption increases breast cancer risk in women even at low levels, complicating the risk-benefit analysis of “moderate” drinking.[1]

Risk-Benefit Analysis and Current Guidelines

The debate over whether any level of alcohol is “safe” has reached a critical juncture.[19,20] Current recommendations from major health organizations emphasize caution and personal risk assessment.[13,19]

Comparing Professional Guidelines (2024-2025)

The American Heart Association (AHA), American College of Cardiology (ACC), and the World Health Organization (WHO) have increasingly harmonized their messages, shifting away from endorsing moderate alcohol for health benefits.[13,19]

Organization	Key Recommendation	“Safe” Threshold
American Heart Association	If you don’t drink, don’t start. Limit intake if you do.	Men: <= 2; Women: <= 1 drink/day
World Health Organization	No level of alcohol is completely safe for health.	No recommended consumption level
Dietary Guidelines (US)	Choice not to drink is healthiest. Drink in moderation.	Men: <= 2; Women: <= 1 drink/day
ACC (High Blood Pressure)	Reducing intake is an effective treatment for HBP.	Abstinence or strict moderation

Net Clinical Benefit vs. Cancer Risk

A significant factor in the changing perception of alcohol is the strong evidence linking it to various cancers, including those of the mouth, throat, esophagus, liver, and breast.[1,19] The International Agency for Research on Cancer classifies alcohol as a Group 1 carcinogen.[1] For many individuals, the marginal (and potentially non-causal) cardiovascular benefit of one drink per day is outweighed by the lifelong cumulative increase in cancer risk.[1,19]

Clinical Synthesis and Evidence-Based Conclusion

The comprehensive evaluation of the cardiovascular effects of alcohol reveals a complex landscape where observational benefits are increasingly at odds with genetic and causal inference data.[1,3,4]

1. Dose-Response Summary: While observational studies continue to produce J-shaped curves for myocardial infarction and ischemic stroke, newer genetic methodologies (Mendelian randomization) suggest these benefits may be artifacts of confounding and lifestyle factors.[1,3,4] In contrast, the risks for hypertension, atrial fibrillation, and hemorrhagic stroke appear to increase linearly or exponentially with consumption.[3,4,12,15]
2. Atherosclerosis and Mechanisms: Alcohol increases HDL cholesterol and decreases fibrinogen, but these changes do not consistently result in reduced structural atherosclerosis as measured by arterial imaging.[2,10,11] Heavy intake remains a primary driver of vascular damage and systemic inflammation.[2]
3. Arrhythmic Impact: There is no clear safe threshold for alcohol regarding atrial fibrillation.[12,15] Alcohol induces both acute electrical changes and chronic structural remodeling (atrial fibrosis) that increase the burden of arrhythmias.[12,28,29,31]
4. Stroke Subtypes: A critical dichotomy exists between ischemic and hemorrhagic stroke.[1,23] Any anti-thrombotic benefit for ischemic stroke is counteracted by the significant increase in hemorrhagic risk, particularly during binge drinking or in individuals with pre-existing hypertension.[1,2,23]
5. Beverage Type: The perceived superiority of red wine is likely a reflection of the “healthy user” profile of wine drinkers rather than a unique pharmacological property of wine polyphenols.[18,22] Ethanol itself remains the primary active agent influencing cardiovascular outcomes.[2]
6. Cardiomyopathy: Chronic heavy drinking (80g/day) is a preventable cause of heart failure.[14,15] ACM is uniquely characterized by its potential for reversibility upon total abstinence.[15,25]

The evidence-based conclusion is that while low-to-moderate alcohol consumption may be statistically associated with certain lower cardiovascular risks in observational cohorts, the benefit is likely overstated and may be non-causal.[1,3,4] High consumption and binge drinking clearly cause substantial harm to cardiac structure and function.[2,12,14,15] From a public health and clinical management perspective, the safest level of consumption is low or zero, especially for populations at high risk for arrhythmias, stroke, or cancer.[1,19] Patients should be counseled that if they do not currently consume alcohol, there is no evidence-based reason to start for “heart health.”[19] Those who do drink should be advised to remain strictly within the limits of one drink per day for women and two for men, with frequent alcohol-free days to mitigate the risk of cumulative structural damage.[19]

References

1. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Food and Nutrition Board; Committee on Review of Evidence on Alcohol and Health, Stone KB, Calonge BN, eds. Review of Evidence on Alcohol and Health. Washington (DC): National Academies Press (US); April 23, 2025.
2. Piano MR. Alcohol’s Effects on the Cardiovascular System. Alcohol Res. 2017;38(2):219-241. doi:10.35946/arcr.v38.2.06
3. Larsson SC, Burgess S, Mason AM, Michaëlsson K. Alcohol Consumption and Cardiovascular Disease: A Mendelian Randomization Study. Circ Genom Precis Med. 2020;13(3):e002814. doi:10.1161/CIRCGEN.119.002814
4. Chien PS, Wong TJ, Tai AS, Shr YH, Yu T. Examining the causal association between moderate alcohol consumption and cardiovascular risk factors in the Taiwan Biobank: a Mendelian randomization analysis. Front Cardiovasc Med. 2024;11:1456777. Published 2024 Oct 2. doi:10.3389/fcvm.2024.1456777
5. Tadokoro T, Oura K, Nakahara M, et al. Genetic Polymorphisms of ALDH2 and ADH1B in Alcohol-Induced Liver Injury: Molecular Mechanisms of Inflammation and Disease Progression in East Asian Populations. Int J Mol Sci. 2025;26(17):8328. Published 2025 Aug 28. doi:10.3390/ijms26178328
6. Li YY, Wang H, Wu JJ, et al. ALDH2 gene G487A polymorphism and coronary artery disease: a meta-analysis including 5644 participants. J Cell Mol Med. 2018;22(3):1666-1674. doi:10.1111/jcmm.13443
7. Sung YF, Lee JT, Hu CJ, Jeng JS, Chiou HY, Peng GS. Impact of ALDH2 genotypes and alcohol consumption on age at first-ever ischemic stroke: A cohort study in Taiwan. Alcohol Clin Exp Res (Hoboken). 2026;50(1):e70217. doi:10.1111/acer.70217
8. Centers for Disease Control and Prevention. About moderate alcohol use. CDC website. Published 2025. https://www.cdc.gov/alcohol/about-alcohol-use/moderate-alcohol-use.html
9. Jiang H, Mei X, Jiang Y, et al. Alcohol consumption and atrial fibrillation risk: An updated dose-response meta-analysis of over 10 million participants. Front Cardiovasc Med. 2022;9:979982. Published 2022 Sep 30. doi:10.3389/fcvm.2022.979982
10. Britton AR, Grobbee DE, den Ruijter HM, et al. Alcohol Consumption and Common Carotid Intima-Media Thickness: The USE-IMT Study. Alcohol Alcohol. 2017;52(4):483-486. doi:10.1093/alcalc/agx028
11. Dahlin Almevall A, Wennberg P, Nyman E, et al. Low to moderate alcohol consumption across two decades and subclinical atherosclerosis at age 60: findings from the Northern Sweden Västerbotten Intervention Programme-visualisation of atherosclerosis (VIPVIZA) study. Front Cardiovasc Med. 2026;12:1710165. Published 2026 Jan 7. doi:10.3389/fcvm.2025.1710165
12. Surma S, Lip GYH. Alcohol and Atrial Fibrillation. Rev Cardiovasc Med. 2023;24(3):73. Published 2023 Mar 1. doi:10.31083/j.rcm2403073
13. Gulati, M, Moore, M, Cibotti-Sun, M. 2025 High Blood Pressure Guideline-at-a-Glance. JACC. 2025 Nov, 86 (18) 1560–1566. https://doi.org/10.1016/j.jacc.2025.07.010
14. Shaaban A, Gangwani MK, Pendela VS, et al. Alcoholic Cardiomyopathy. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK513322/
15. Domínguez F, Adler E, García-Pavía P. Alcoholic cardiomyopathy: an update. Eur Heart J. 2024;45(26):2294-2305. doi:10.1093/eurheartj/ehae362
16. Harvard T.H. Chan School of Public Health. Is wine fine, or beer better? The Nutrition Source. https://nutritionsource.hsph.harvard.edu/is-wine-fine-or-beer-better/
17. Institute for Health Metrics and Evaluation. Alcohol use. IHME website. https://www.healthdata.org/research-analysis/health-topics/alcohol-use
18. Lucerón-Lucas-Torres M, Saz-Lara A, Díez-Fernández A, et al. Association between Wine Consumption with Cardiovascular Disease and Cardiovascular Mortality: A Systematic Review and Meta-Analysis. Nutrients. 2023;15(12):2785. Published 2023 Jun 17. doi:10.3390/nu15122785
19. Piano MR, Marcus GM, Aycock DM, et al. Alcohol Use and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2025;152(1):e7-e21. doi:10.1161/CIR.0000000000001341
20. Rolver MG, Emanuelsson F, Nordestgaard BG, Benn M. C-reactive protein and prospective cardiometabolic risk: observational and Mendelian randomization study of ischemic stroke and all-cause death. Cardiovasc Diabetol. 2025;25(1):11. Published 2025 Dec 11. doi:10.1186/s12933-025-03028-5
21. Bekkevold OJ, Damås JK, Brumpton BM, Åsvold BO. The causal role of C-reactive protein and interleukin-6 on anxiety and depression symptoms and life satisfaction: Mendelian randomisation analyses in the HUNT study. Psychol Med. 2023;53(16):7561-7568. doi:10.1017/S0033291723001290
22. Li H, Förstermann U. Red wine and cardiovascular health. Circ Res. 2012;111(8):959-961. doi:10.1161/CIRCRESAHA.112.278705
23. Toubasi AA, Al-Sayegh TN. Alcohol Use and Types and Ischemic Stroke: A Systematic Review and Meta-Analysis. Eur Neurol. 2025;88(3-4):140-150. doi:10.1159/000547945
24. Rimm EB, Williams P, Fosher K, Criqui M, Stampfer MJ. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ. 1999;319(7224):1523-1528. doi:10.1136/bmj.319.7224.1523
25. Estruch R, Fernández-Solá J, Mont L, et al. Reversibilidad de la miocardiopatía alcohólica con la abstinencia: presentación de dos casos [Reversibility of alcoholic myocardiopathy with abstinence: presentation of 2 cases]. Med Clin (Barc). 1989;92(2):69-71.
26. Howie EK, Sui X, Lee DC, Hooker SP, Hébert JR, Blair SN. Alcohol consumption and risk of all-cause and cardiovascular disease mortality in men. J Aging Res. 2011;2011:805062. doi:10.4061/2011/805062
27. Niu C, Dong J, Zhang P, et al. The global burden of cardiovascular disease attributable to high alcohol use from 1990 to 2021: an analysis for the global burden of disease study 2021. Front Public Health. 2025;13:1541641. Published 2025 Feb 14. doi:10.3389/fpubh.2025.1541641
28. Qiao Y, Shi R, Hou B, et al. Impact of Alcohol Consumption on Substrate Remodeling and Ablation Outcome of Paroxysmal Atrial Fibrillation. J Am Heart Assoc. 2015;4(11):e002349. Published 2015 Nov 9. doi:10.1161/JAHA.115.002349
29. Huang Z, Luo C, Wu Z, Zheng B. Electrophysiological Mechanisms and Therapeutic Potential of Calcium Channels in Atrial Fibrillation. Rev Cardiovasc Med. 2025;26(6):33507. Published 2025 Jun 25. doi:10.31083/RCM33507